Cost-Effectiveness of Bevacizumab Biosimilar LY01008 Combined With Chemotherapy as First-Line Treatment for Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small Cell Lung Cancer

Objective: To investigate whether LY01008, a locally developed bevacizumab biosimilar agent, is appropriate for widespread use among Chinese advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC) patients, our current study was designed to evaluate the cost-effectiveness of first-line...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Xia, Liu, Qiao, Zhou, Zhen, Yi, Lidan, Peng, Liubao, Wan, Xiaomin, Zeng, Xiaohui, Tan, Chongqing, Li, Sini
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9062292/
https://www.ncbi.nlm.nih.gov/pubmed/35517823
http://dx.doi.org/10.3389/fphar.2022.832215

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9062292/
https://www.ncbi.nlm.nih.gov/pubmed/35517823
http://dx.doi.org/10.3389/fphar.2022.832215

Ejemplares similares